Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon Bollag

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Cancer Cell|September 14, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Cancer Research|June 17, 2010
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma modelsHong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 28, 2015
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelDaniele Perna, Florian A Karreth, Alistair G Rust, et al.
Clinical and Experimental Medicine|December 8, 2018
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumorsYemarshet K Gebreyohannes, Elizabeth A Burton, Agnieszka Wozniak, et al.
International Journal of Cancer|July 17, 2010
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutationJeanne Tie, Peter Gibbs, Lara Lipton, et al.
Molecular Cell|July 21, 2004
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterasesKam Y J Zhang, Graeme L Card, Yoshihisa Suzuki, et al.
Nature Biotechnology|February 3, 2005
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug designGraeme L Card, Landy Blasdel, Bruce P England, et al.
Science Signaling|December 5, 2013
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasErnesto Diaz-Flores, Hana Goldschmidt, Philippe Depeille, et al.
Pigment Cell & Melanoma Research|July 30, 2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyThomas Botton, Iwei Yeh, Tyrrell Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Cancer Cell|September 14, 2016
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingZoi Karoulia, Yang Wu, Tamer A Ahmed, et al.
Cancer Research|June 17, 2010
RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma modelsHong Yang, Brian Higgins, Kenneth Kolinsky, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 28, 2015
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelDaniele Perna, Florian A Karreth, Alistair G Rust, et al.
Clinical and Experimental Medicine|December 8, 2018
PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumorsYemarshet K Gebreyohannes, Elizabeth A Burton, Agnieszka Wozniak, et al.
International Journal of Cancer|July 17, 2010
Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutationJeanne Tie, Peter Gibbs, Lara Lipton, et al.
Molecular Cell|July 21, 2004
A glutamine switch mechanism for nucleotide selectivity by phosphodiesterasesKam Y J Zhang, Graeme L Card, Yoshihisa Suzuki, et al.
Nature Biotechnology|February 3, 2005
A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug designGraeme L Card, Landy Blasdel, Bruce P England, et al.
Science Signaling|December 5, 2013
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasErnesto Diaz-Flores, Hana Goldschmidt, Philippe Depeille, et al.
Pigment Cell & Melanoma Research|July 30, 2013
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapyThomas Botton, Iwei Yeh, Tyrrell Nelson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2010
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerEric W Joseph, Christine A Pratilas, Poulikos I Poulikakos, et al.
Pageof 9